Views & Analysis Orphan drugs: overcoming barriers to market access What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.
Partner Content Partner Content Orphan medicines, advances, access and affordability LONDON, UNITED KINGDOM, April 19th 2017:
Views & Analysis Rethinking rare diseases: treat the whole patient CRDN wants to break down barriers in communication between rare disease patients, HCPs and industry.
Views & Analysis Are European incentives speeding access in rare cancer treat... Examining the impact of support programmes for orphan treatments.
Views & Analysis World Scleroderma Day: raising awareness Highlighting the symptoms of scleroderma, latest research and a genuine ‘diary’ experience from a US patient.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
